person
as of 2026-07-01René Kahn, Prof. Dr.
René Kahn, MD, PhDRené S Kahn
ORCID 0000-0001-5909-8004
at a glance
Roles: Principal Investigator, Study Chair, Author
KOL signal score 11
3 publications · 1 high-value
Cross-drug reach: 1 competitor drugs
Synthesized from structured facts only — each point cited above.
Profile
Affiliation
UMC Utrecht
Roles
Principal Investigator, Study Chair, Author
KOL signal
11
Publications
3 (1 high-value)
Trial investigator
yes
Publishes on
1 drugs
Trials led
2
Placebo-controlled Trial in Subjects at Ultra-high Risk for Psychosis With Omega-3 Fatty Acids in Europe
NCT02597439Phase 4Completed
Optimization of Treatment and Management of Schizophrenia in Europe
NCT01248195Phase 4Completed
Publications & congress
3
Generalizability of the Results of Efficacy Trials in First-Episode Schizophrenia: Comparing Outcome and Study Discontinuation of Groups of Participants in the Optimization of Treatment and Management of Schizophrenia in Europe (OPTiMiSE) Trial.
The Journal of clinical psychiatry · 2023 · high-value
Cognitive impairment preceding the onset of the first psychosis episode in schizophrenia.
Molecular psychiatry · 2026
Association of Complement and Coagulation Pathway Proteins With Treatment Response in First-Episode Psychosis: A Longitudinal Analysis of the OPTiMiSE Clinical Trial.
Schizophrenia bulletin · 2023
Facts & assertions
0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
publishes on
drug
STUDY_CHAIR
PRINCIPAL_INVESTIGATOR